|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-7
|
|
pubmed:abstractText |
Filgrastim was developed to treat chemotherapy-induced neutropenia. This phase III study was designed to demonstrate bioequivalence of Amgen filgrastim and a biosimilar filgrastim developed by Hospira (Study GCF071; sponsored by Hospira).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0240
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
504-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20926897-Adult,
pubmed-meshheading:20926897-Aged,
pubmed-meshheading:20926897-Aged, 80 and over,
pubmed-meshheading:20926897-Antineoplastic Agents,
pubmed-meshheading:20926897-Breast Neoplasms,
pubmed-meshheading:20926897-Double-Blind Method,
pubmed-meshheading:20926897-Europe,
pubmed-meshheading:20926897-Female,
pubmed-meshheading:20926897-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:20926897-Humans,
pubmed-meshheading:20926897-Immunosuppressive Agents,
pubmed-meshheading:20926897-Middle Aged,
pubmed-meshheading:20926897-Neutropenia,
pubmed-meshheading:20926897-Recombinant Proteins,
pubmed-meshheading:20926897-Therapeutic Equivalency,
pubmed-meshheading:20926897-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
|
|
pubmed:affiliation |
Abt. Innere Medizin I, Medizinische Universitatsklinik, Freiburg, Germany. cornelius.waller@uniklinik-freiburg.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
